These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 9927120)
1. Recombinant human erythropoietin and blood management in pediatric spine surgery. Roye DP Orthopedics; 1999 Jan; 22(1 Suppl):s158-60. PubMed ID: 9927120 [No Abstract] [Full Text] [Related]
2. Blood loss and transfusion management in spinal surgery. Dekutoski MB Orthopedics; 1999 Jan; 22(1 Suppl):s155-7. PubMed ID: 9927119 [No Abstract] [Full Text] [Related]
3. Erythropoietic therapy: cost efficiency and reimbursement. Jaspan D Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S19-29. PubMed ID: 17687067 [TBL] [Abstract][Full Text] [Related]
4. Questionable conclusions about epoetin alfa. Kruse MW; Lee JJ Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355 [No Abstract] [Full Text] [Related]
5. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437 [TBL] [Abstract][Full Text] [Related]
6. Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. Lefebvre P; Vekeman F; Cremieux PY Ann Pharmacother; 2010 Mar; 44(3):595; author reply 595-6. PubMed ID: 20179253 [No Abstract] [Full Text] [Related]
8. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573 [TBL] [Abstract][Full Text] [Related]
9. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Ortega A; Dranitsaris G; Puodziunas AL Cancer; 1998 Dec; 83(12):2588-96. PubMed ID: 9874467 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood. Driver PS Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688 [TBL] [Abstract][Full Text] [Related]
18. Blood conservation in the critically ill. Thomas J; Martinez A Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S11-8. PubMed ID: 17687066 [TBL] [Abstract][Full Text] [Related]
19. Proceedings of the roundtable of experts in surgery blood management. Vienna, Austria, April 7-9, 1995. Semin Hematol; 1996 Apr; 33(2 Suppl 2):1-80. PubMed ID: 8999552 [No Abstract] [Full Text] [Related]
20. Switching from i.v. to s.c. epoetin in hemodialysis patients. Knauss MD; Walton T; Macon EJ Am J Health Syst Pharm; 2002 Sep; 59(18):1783-4. PubMed ID: 12298119 [No Abstract] [Full Text] [Related] [Next] [New Search]